Compare Eaton Corporation plc (ETN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Sana Biotechnology Inc — how do they compare? Eaton Corporation plc trades at $428.87 (market cap $164.88B), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: Eaton Corporation plc is far larger — about 197.1× Sana Biotechnology Inc's market cap, and Eaton Corporation plc pays a 1.04% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Sana Biotechnology Inc for 23 Days on average.
| ETN | SANA | |
|---|---|---|
Market Cap | $164.88B | $836.71M |
Volume | 2,535,086 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $459.96 | $5.92 |
52-Week Low | $315.82 | $2.68 |
Typical Hold Time | 31 Days | 23 Days |
Enterprise Value | $185.51B | $749.96M |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $430.25, down 0.25% with bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains healthy margins (12.75% net income), and benefits from strategic acquisitions in data center and aerospace markets. Analyst consensus remains strongly bullish with a $502.38 price target, though technical indicators show near-term pressure with support at $418.
ETN presents a compelling growth story driven by AI data center demand and grid modernization trends, but faces execution risks from recent acquisitions and competitive pressure from peers like Vertiv. The stock's premium valuation (P/E 43.23) requires sustained earnings growth to justify, making upcoming Q3 earnings on November 5 critical for momentum.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
